Does melatonin prevent diabetes and obesity? What science says

Editorial note: This article was originally published in the past and has been updated according to scientific and divulgative criteria. The information presented here is for informational purposes only and does not replace medical advice.

IN BRIEF

• Melatonin is a hormone linked to the sleep-wake rhythm that, in experimental models, influences metabolism, inflammation, and adipose composition.
• Animal studies show favorable effects of melatonin supplementation on weight, steatosis, and insulin sensitivity; in people, results are variable.
• Genetic variants in the melatonin receptor (MTNR1B) are associated with differences in fasting glucose levels and a modest, albeit increased, risk of diabetes.
• The evidence does not authorize generalized therapeutic claims: dose, timing, context, and genetics modulate the effects.
• Before taking melatonin for metabolic reasons, it is necessary to consult a healthcare professional; promoting sleep remains a pillar of metabolic prevention.

Abstract: what does science say?

Melatonin is a key mediator of the circadian rhythm with antioxidant and inflammation-modulating actions. In animal models, nocturnal or oral supplementation reduced weight gain, adipose inflammation, and metabolic alterations, and modified the gut microbiota. In clinical studies and meta-analyses on human patients, the results are heterogeneous: some reviews report a modest improvement in glycemic parameters, while others show no effects or even a reduction in insulin sensitivity under specific temporal conditions or genotypes. Furthermore, variants of the melatonin receptor gene (MTNR1B) are associated with variations in fasting glucose levels and a small increase in the risk of diabetes. Overall, the literature suggests biological plausibility and consistent experimental evidence in animals, while in people, larger, controlled studies focusing on dose, timing, and genetic subgroups are needed. Prudent interpretation avoids definitive causal conclusions and emphasizes the need to contextualize melatonin within interventions on sleep, diet, and physical activity.

Simple definition of the topic

Melatonin is a hormone produced mainly by the pineal gland during the night; it regulates sleep and signals the body's day/night cycle. In recent years, it has also been studied for its role in energy metabolism, inflammation regulation, and adipose tissue function. The central question is whether melatonin can, in addition to improving sleep, help reduce the risk of obesity and diabetes or improve metabolic parameters in people already at risk or affected by the disease.

What the available evidence shows

Experimental evidence in animal models is consistently favorable: melatonin administrations limit weight gain induced by high-fat diets, improve insulin sensitivity, and reduce inflammation and hepatic steatosis [2][3][4]. Mechanistic reviews explain how melatonin affects peripheral tissues, the gut microbiota, and thermogenesis [1]. In human clinical studies, the results are mixed: meta-analyses suggest modest effects on fasting glycemia and insulin sensitivity indices, but differences in doses, duration, and populations make the results inconclusive [5]. Recent experimental data in human adipose tissue indicate that, under certain temporal conditions, melatonin can reduce the local insulin response, suggesting effects dependent on timing and biological context [7].

Dose, frequency, context, and interpretative limits

The observed effects depend on the dose (pharmacological vs. physiological dose), the route of administration, the time of day (evening vs. morning intake), the duration of treatment, and the biological characteristics of the subjects (age, metabolic status, genotype). Many animal studies use high doses and controlled conditions that do not directly translate into clinical practice. In humans, the variability of protocols and the presence of confounding factors (diet, physical activity, sleep quality) limit reliable causal inferences.

Plausible biological mechanisms

From a biological perspective, the plausibility of a metabolic effect of melatonin is supported by multiple integrated mechanisms. Melatonin regulates the activity of MT1 and MT2 receptors present in metabolic tissues, with effects on insulin secretion, peripheral sensitivity, and lipid metabolism [1]. It acts as a direct antioxidant and as a modulator of antioxidant enzymes, reducing oxidative stress that contributes to insulin resistance. It influences local inflammation in adipose tissue by decreasing the expression of pro-inflammatory cytokines and reducing the presence of macrophages in inflamed adipose areas [4][8]. Furthermore, melatonin appears to modulate the function of brown adipose tissue and the so-called 'browning' of white tissue, increasing energy expenditure and thermogenesis in animal models [3]. Interaction with the gut microbiota is another channel of action: some studies show that melatonin administration alters bacterial composition towards communities associated with improved lipid and glycemic metabolism [2]. These mechanisms are consistent with each other and explain the consistency of experimental results; however, their clinical translation in humans remains to be precisely defined.

Experimental evidence: what animal studies say

Numerous studies on rodents show that melatonin administration can attenuate weight gain induced by high-calorie diets, reduce hepatic lipid accumulation, improve lipid profiles, and decrease inflammatory markers in adipose tissue [2][4][8]. In models with genetic obesity (ob/ob) and in dietary models, melatonin improved adipokines, decreased adipocyte hypertrophy, and reduced the formation of 'crown-like structures', signals of adipose inflammation [5][8]. Some studies have also shown an increase in brown adipose tissue activity and an increase in energy expenditure, with possible involvement of FGF21 and mitochondrial pathways [3]. It is important to remember that in animals, dosages and methods not equivalent to common human supplementation can be used, and the duration of treatment is often different from clinical practice. Despite repeated evidence in experimental models, clinical translation requires caution due to species-specific differences and the control of environmental factors in animal models.

Clinical evidence: human studies and genetics

In humans, research includes randomized clinical trials, observational studies, and meta-analyses. Some meta-analyses of controlled studies report a modest reduction in fasting glycemia and partial improvements in insulin sensitivity indices after melatonin supplementation, especially in individuals with altered baseline glycemia [5]. However, the results are heterogeneous due to dosage, duration, and studied population. More recently, experiments on human adipose tissue show that melatonin exposure in the evening phase can reduce the local insulin response, suggesting that the timing of intake relative to meals can be crucial [7]. On the genetic front, variants in the MTNR1B melatonin receptor gene are associated with differences in fasting glucose levels and a modest, albeit increased, risk of diabetes in the studied population, indicating that the response to melatonin can be modified by the individual genetic profile [6]. These data open the way for personalized medicine hypotheses, but do not currently authorize generalized clinical recommendations.

What it means in practice

For the general public, the practical message is sober and pragmatic. Melatonin is a hormone with established functions on sleep and, in experimental models, shows favorable effects on weight and metabolism. However, in human patients, metabolic effects are variable and depend on dose, time of intake, initial metabolic status, and genetic variants. There is insufficient evidence to recommend melatonin as a primary strategy for preventing or treating obesity or diabetes. It is reasonable to consider that improving sleep quality and regularity — with good sleep hygiene practices, reduction of exciting evening stimuli (caffeine, bright screens), and lifestyle management — is a useful and non-risky component in preventive strategies. The use of melatonin for metabolic purposes alone should be evaluated on a case-by-case basis with a doctor, especially when sleep disorders, concomitant pharmacological therapies, or relevant genetic variants coexist. Avoid high-dose self-prescription and consider that the time of intake can modify the effects.

KEY POINTS TO REMEMBER

• Melatonin regulates the sleep-wake rhythm and has antioxidant and anti-inflammatory activity.
• In animal models, melatonin administration reduces weight gain, adipose inflammation, and metabolic alterations [2][3][4].
• In humans, clinical evidence is heterogeneous: meta-analyses report modest effects on glycemia, but no definitive proof of preventive benefit on obesity or diabetes [5].
• MTNR1B receptor variants are associated with differences in glucose levels and a modest, albeit increased, risk of diabetes [6].
• The timing of intake and individual profile (genetics, metabolic status) seem to influence the effects; always consult a doctor before using melatonin for metabolic purposes [7].

Limitations of the evidence

It is necessary to distinguish between observational studies, experimental evidence in animals, and randomized clinical trials. Observational studies can show associations between sleep alterations, melatonin levels, and metabolic risk, but do not establish causality. Animal experiments provide causal information on mechanisms but use dosages and conditions not always generalizable to humans. In clinical trials, the heterogeneity of dosages, duration, populations, and outcomes makes it difficult to draw clear conclusions: some results are favorable, others neutral or contrary under certain temporal conditions or in the presence of genetic variants. Common methodological issues include limited samples, selection bias, absence of stratification by genotype, and lack of rigorous monitoring of intake timing relative to meals. Therefore, interpretative caution and further controlled, large-scale studies aimed at defining dose, time, and subgroups with differentiated responses are needed.

Editorial conclusion

Research on melatonin, sleep, and metabolism has made significant progress: there is a solid biological basis and consistent experimental results that justify clinical interest. However, translating these results into practical recommendations requires further quality clinical evidence that considers dose, timing, and individual variability, including genetic predisposition. For now, promoting good sleep and healthy lifestyles remains the strategy with the best evidence for metabolic prevention. The therapeutic use of melatonin for metabolic purposes must be evaluated with caution and under medical supervision.

Editorial note

Article updated according to scientific accuracy and transparency criteria. The information does not replace medical consultation. For therapeutic decisions, consult your doctor or specialist.

SCIENTIFIC RESEARCH

1. Mechanisms of Melatonin in Obesity: A Review. https://doi.org/10.3390/ijms23010218. [review; mechanisms].
2. Melatonin prevents obesity through modulation of gut microbiota in mice. https://doi.org/10.1111/jpi.12399. [animal study; microbiota].
3. Suppression of obesity by melatonin through increasing energy expenditure and accelerating lipolysis in mice fed a high‑fat diet. https://doi.org/10.1038/s41387-022-00222-2. [animal study; thermogenesis and FGF21].
4. Melatonin Supplementation Decreases Hypertrophic Obesity and Inflammation Induced by High‑Fat Diet in Mice. https://doi.org/10.3389/fendo.2019.00750. [animal study; adipose inflammation].
5. The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta‑Analysis of Randomized Controlled Trials. https://doi.org/10.1055/a-0752-8462. [meta-analysis RCT; glycemia].
6. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. https://doi.org/10.1038/ng.288. [genetics; MTNR1B].
7. Melatonin decreases human adipose tissue insulin sensitivity. https://doi.org/10.1111/jpi.12965. [study on human adipose tissue; timing and insulin sensitivity].
8. Melatonin reduces obesity and restores adipokine patterns and metabolism in obese (ob/ob) mice. https://doi.org/10.1016/j.nutres.2015.07.001. [animal study; ob/ob].